WASHINGTON, D.C.—Taking high-dose non-steroidal anti-inflammatory drugs (NSAIDs) with a TNF inhibitor as an ankylosing spondylitis (AS) patient is linked with a 61% decrease in the chances your disease will progress, suggesting there may be a synergy when the drugs are used together, according to a longitudinal observational study from researchers at the University of California, San Francisco (UCSF).
Explore this issueMarch 2017
Also by this Author
The findings were highlighted at the 2016 ACR/ARHP Annual Meeting in a Discovery abstract session that also included findings on allopurinol and chronic kidney disease in gout patients and the effects of poverty on SLE damage.1
NSAIDs & AS
TNF inhibitors and NSAIDs have shown mixed results in preventing AS progression. Researchers set out to gauge the benefit seen in those taking TNF inhibitors and NSAIDs together. They looked at 538 patients in the Prospective Study of Outcomes in Ankylosing Spondylitis, with patients followed for at least two years and a median of four. X-rays were collected every two years, with a determination of progression by mSASSS, the modified Stoke Ankylosing Spondylitis Spinal Score.